Lyell Immunopharma
LYEL
Lyell Immunopharma (LYEL) news
Recent news
Lyell's Lyl273 phase 1/2 data, FDA meeting now due in 2027
AInvest Wire · Sep 10, 2026Lyell completes Lyl273 manufacturing transfer to Lyfe
AInvest Wire · Sep 10, 2026Lyell Immunopharma: Additional clinical data and end-of-phase 1 FDA meeting expected in 2027
AInvest Wire · Sep 10, 2026Lyell Immunopharma Q2 operating income USD -47.337 million
AInvest Wire · Aug 6, 2026Lyell Immunopharma Q2 operating expenses USD 47.341 million
AInvest Wire · Aug 6, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.